

# Baker Yeast a Greener Catalyst for Synthesis of Diverse Heterocyclic Compound: A Review

Mr. Khan Shoyeab Mutalib<sup>1</sup> and Mr. Gokul Jaykisan<sup>2</sup>

Department of Chemistry

Anjuman Islam Janjira Degree College of Science, Murud-Janjira, Raigad<sup>1,2</sup>

**Abstract:** *Saccharomyces cerevisiae*, usually referred to as baker's yeast, has gained important importance as a gentle, low-cost, environmentally benign catalyst. At the start it had been largely used as an economical catalyst for the enantioselective reduction of carbonyl compounds. Over the last decade, baker's yeast has found versatile chemical change applications in numerous organic transformations. Several multicomponent reactions were conjointly catalyzed by baker's yeast. Numerous heterocyclic scaffolds with huge biological activities were synthesized by using baker's yeast as catalyst at temperature. During this communication, we've got summarized baker's yeast catalyzed numerous organic transformations focusing totally on heterocyclic synthesis.

**Keywords:** Microbiome, Plant Growth-Promoting Bacteria, etc.

## I. INTRODUCTION

The art of organic synthesis has advanced staggeringly over the last decade. However, the conception of ideal synthesis is nevertheless to be complete for the synthesis of advanced natural product. Among several reactions, multicomponent reactions (MCRs) cover several aspects of "ideal synthesis" and, are shown to be a detailed match.[1] In MCRs, 3 or additional reacting parts type a product during which majority of the atoms from reacting parts are incorporated. The ultimate product arises through many elementary steps that are generally reversible except one irreversible step that drives the reaction within the forward direction. Therefore, MCRs are categorized as special class of cycle successive reaction. [2]

The first MCR was discovered by Laurent and Gerhard in 1838 and, currently MCRs have become a mainstay in combinatorial synthesis as well as diversity-oriented synthesis (DOS) for rapid library development.[3] The development of Passerini three component reaction (P-3CR) in 1921[4] and Ugi four component reaction (U-4CR) in 1959,[5] inspired the scientific community to develop many new isocyanide-based multicomponent reactions (IMCRs) as well as non-isocyanide based MCRs (NIMCRs).[6] Over the past decade, MCRs in particular IMCRs and, recently NIMCRs played a pivotal role in medicinal, peptidomimetic chemistry, and drug discovery with the recent advancement of high-throughput screening (HTS). [7]

An ideal MCR is usually administered in an exceedingly single vessel during which all the reactants still as reagents square measure value-added at the same time. beneath same reaction conditions, ordered elementary steps permit coupling of all reactants to create the ultimate product. However, the reversible and irreversible nature of each elementary step determines the success of one-pot MCRs. [8].


It is noteworthy that, except the well-established MCRs, majority of the new MCRs needs catalysts [9] (e. g. Lewis acids, Bronsted acids) and additives now and then to drive the general equilibrium into the forward direction. usually times, property is Associate in Nursinging obstacle to seek out the correct catalyst. Therefore, chemical synthesis needs a tedious and long screening of many catalysts (50-100 or additional) to attain a minimum of ninety fifth or more enantioselectivity. it's noteworthy that, biomimetic reactions during which every elementary step square measure irreversible, fall under the special Type-III MCR class during which every elementary step issue irreversibly to create final product.[10] In contrary to chemical catalysts, enzymes catalyse several transformations in nature with high degree of selectivities. In their extraordinary discoveries within the Eighties, Klibanov and Büchner tried that protein chemical process (e. g. fermentation) doesn't essentially ought to have live cell conditions. [11]

Enzymes have the flexibility to face-recognize enantiotropic teams of racemic compounds and so, will turn reactions stereo selectively.[12] to the current finish, combinatorial bio-catalysis has been utilized for the event of natural product derivatives.[13] Few enzymes are used for dynamic kinetic resolution (DKR) of racemates (meso compounds) via the reaction of their organic compound functionalities, N/O-acylation, amino transfer to call many.[14] many catalyst approaches are utilized for the DKR of MCR merchandise or beginning materials for development of diastereoselective MCRs.[15] but, enzymes were comparatively underexplored as potential catalysts in MCRs because of their sleeping around, unstable nature and, usually times the need of co-factors.

## II. BAKER'S YEAST


Yeasts square measure a member of fungi family and being single whole-cell organism. relying upon species and surroundings, their size might vary from 3-4  $\mu\text{m}$  with few exceptions. These prolate cells square measure one in all the earliest microorganisms that were domesticated. usually they're classified into four categories: (a) organic process yeast, (b) Distiller's and Wine yeast, (c) Brewer's yeast, (d) Baker's yeast. they are available from totally different strains of genus *Saccharomyces cerevisiae* (SC) that is that the common scientific name of yeast.

Majority of famous yeasts square measure mesophilic and grow either in slightly acidic or neutral pH scale surroundings. Typically, industrially used SC grows best at 37°C. Brewer's yeast (BRY) basically differs from Baker's yeast (BY) in terms of composition. The bitter tasting BRY contains strains of SC having additional alcohol manufacturing capability. BRY was conjointly wont to treat several medical conditions e.g., eczema, urns, diarrhoea and polygenic disease to call a number of. [16]




## III. BIGINELLI REACTION

In 1993, Biginelli and co-workers discovered a straightforward one-pot three component reaction (B-3CR) for the synthesis of biologically relevant 3,4-dihydropyrimidin-2-(1H)-ones or 3,4- dihydropyrimidin-2-(1H)-thiones by employing benzaldehyde, ethyl acetoacetate and urea in the presence of a strong acid.[17] The product 3,4-dihydropyrimidin-2-(1H)-one, Scheme 1) is commonly referred to as the Biginelli compound. Since then, the B-3CR has become an important NIMCR for the synthesis medicinally important compounds containing the Biginelli motif.




Scheme-1



#### IV. HANTZSCH REACTION


In 1881, Arthur Rudolf Hantzsch discovered a convenient synthesis of 1,4-dihydropyridines by employing two equivalents of  $\beta$ -diketoester, one equivalent of formaldehyde in the presence of ammonia.[18] 1,4-dihydropyridine dicarboxylate is commonly known as the Hantzsch compound or 1,4-DHP.[26] The 1,4-DHP motif is an important pharmacophore which is present in many medicinally active agents. Interestingly, the 1,4-DHP motif can be aromatized in aqueous solution using various catalyst including ferric chloride, chromic oxide, manganese dioxide or potassium permanganate, to obtain pyridine compounds.[19]

In 2005, Lee reported a convenient method of synthesizing 1,4-DHP motifs 14 in moderate yields using fermented BY, glucose (5b) and 3-aminocrotonitrile (13a) or ammonium acetate (13b) at room temperature in phosphate buffer (pH 7.0).[20]



### V. MISCELLANEOUS REACTIONS

Most recently, a one-pot protocol for the synthesis of pent substituted thiopyridones catalyzed BY was reported by Chavan and co-workers.[21] The reaction works in a number of protic as well as aprotic solvents and provided moderate to excellent yield. It is noteworthy that a lower yield has been reported when water was used as a solvent compared to other solvents. However, the reaction provided best yield (93%) when ethanol was used as the solvent and 1 g of BY was employed and the reaction was carried out for 40 minutes.



### VI. CONCLUSION

The preceding survey of BY catalyzed multicomponent reaction shows that it's growing space of analysis within the field of organic synthesis and biocatalysts. during this minireview, the reactions are classified in step with the name reaction MCRs. Whenever attainable, plausible mechanism of reactions likewise as at the situation of

the catalyst projected by the authors, has been represented. it's expected that this minireview can stimulate more analysis within the space of accelerator. Since BY consists of the many enzymes, and, therefore, more study is needed to pinpoint role of individual enzymes within the chemical {process chemicalchange chemical action} process and therefore the organic compound residues in their situation.

#### REFERENCES

- [1] T. Gaich, P. S. Baran, *J. Org. Chem.*, 2010, 75, 4657–4673. b) P. A. Wender *Chem. Rev.*, 1996, 96, 1–2. c) P. A. Wender *Nat. Prod. Rep.* 2014, 31, 433–440.
- [2] a) A. Domling, I. Ugi, *Angew. Chem. Int. Ed.*, 2000, 39, 3168–3210. b) L. F. Tietze, *Chem. Rev.*, 1996, 96, 115.
- [3] a) A. Laurent, C. F. Gerhard, *Ann. Chim. Phys.* 1838, 66, 181–195. b) S. L. Schreiber, *Science*, 2000, 287, 1964–1969. c) M. D. Burke, S. L. Schreiber, *Angew. Chem. Int. Ed.* 2004, 43, 46–58. d) D. S. Tan, *Nat. Chem. Biol.* 2005, 1, 74–84.
- [4] M. Passerini, L. Simone, *Gazz. Chim. Ital.* 1921, 51, 126–129.
- [5] I. Ugi, R. Meyr, U. Fetzer, C. Steinbrückner, *Angew. Chem. Int. Ed.* 1959, 71, 386–386.
- [6] a) L. E. Kaim, L. Grimaud, J. Oble, *Angew. Chem. Int. Ed.*, 2005, 44, 7961–7964. b) L. E. Kaim, M. Gizolme, L. Grimaud, *Org. Lett.*, 2006, 8, 5021–5023. c) S. Santra, P. R. Andreana, *Org. Lett.* 2007, 9, 5035–5038. d) S. Santra, P. R. Andreana, *Angew. Chem. Int. Ed.* 2011, 50, 9418–9422. e) K. M. Allan, C. D. Gilmore, B. M. Stoltz, *Angew. Chem. Int. Ed.* 2011, 50, 4488–4491. f) N. Elders, D. van der Born, L. J. D. Hendricks, B. J. J. Timmer, A. Krause, E. Janssen, F. J. J. D. Kanter, E. Ruijter, R. V. A. Orru, *Angew. Chem. Int. Ed.* 2009, 48, 5856–5859.
- [7] a) J. Jordi, D. Guggiana-Nilo, A. D. Bolton, S. Prabha, K. Ballotti, K. Herrera, A. J. Rennekamp, R. T. Peterson, T. A. Lutz, F. Engert, *Sci. Adv.* 2018, 4, eaav1966, 1–15. b) J. R. Broach, J. Thorner, *Nature*, 1996, 384, 14–16. c) B. Liu, S. Li, J. Hu *Am. J. Pharmacogenomic* 2004, 4, 263–276.
- [8] I. Ugi, *J. Prakt. Chem.* 1997, 339, 499–516.
- [9] M. J. Climent, A. Corma, S. Iborra, *RSC Adv.* 2012, 2, 16–58.
- [10] N. Puri, S. Hünsch, C. Sund, I. Ugi, J. Chattopadhyaya, *Tetrahedron* 1995, 51, 2991–3014.
- [11] a) A. M. Klivanov, *Nature* 2001, 409, 241–246. b) A. Zaks, A. M. Klivanov, *Science* 1984, 224, 1249–1251.
- [12] M. Engleder, G. A. Strohmeier, H. Weber, G. Steinkellner, E. Leitner, M. Müller, D. Mink, M. Schürmann, K. Gruber, H. Pichler, *Angew. Chem. Int. Ed.* 2019, 58, 7480–7484.
- [13] a) F. Li, X. Zhang, H. Renata, *Curr. Opin. Chem. Biol.* 2019, 49, 25–32. b) C. Fuganti, *Pure Appl. Chem.* 1990, 62, 1449–1452.
- [14] R. Csuk, B. I. Glänzer, *Chem. Rev.* 1991, 91, 49–97.
- [15] a) K. S. Atwal, B. N. Swanson, S. E. Unger, D. M. Floyd, S. Moreland, A. Hedberg, B. C. O'Reilly *J. Med. Chem.* 1991, 34, 806–811. b) G. J. Grover, S. Dzwonczyk, D. M. McMullen, D. E. Normandin, C. S. Parham, P. G. Sleph, S. Moreland *J. Cardiovasc. Pharmacol.* 1995, 26, 289–294. c) A. K. Prasad, C. Mukherjee, S. K. Singh, R. Brahma, R. Singh, R. K. Saxena, C. E. Olsen, V. S. Parmar *J. Mol. Catal. B: Enzym.* 2006, 40, 93–100.
- [16] P. Hosseinzadeh, M. H. Javanbakht, S.-A. Mostafavi, M. Djalali, H. Derakhshanian, H. Hajianfar, A. Bahonar, A. Djazayeri *Int. J. Prev. Med.* 2013, 4, 1131–1138.
- [17] a) W. Su, J. Li, Z. Zheng, Y. Shen, *Tetrahedron Lett.* 2005, 46, 6037–6040. b) G. Maiti, P. Kundu, C. Guin, *Tetrahedron Lett.* 2003, 44, 2757–2758. c) B. C. O'Reilly, K. S. Atwal, *Heterocycles* 1987, 26, 1185–1188. d) P. Biginelli, *Ber.* 1891, 24, 1317–1319.
- [18] A. Hantzsch, *Chem. Ber.* 1881, 14, 1637–1638.
- [19] A. Meyers, M. S. David, *Chem. Rev.* 1982, 82, 223–243.
- [20] J. J. Xia, G. W. Wang, *Synthesis*, 2005, 14, 2379–2383 and references therein.
- [21] J. H. Lee, *Tetrahedron Lett.* 2005, 46, 7329–7330.
- [22] A. S. Chavan, A. S. Kharat, M. R. Kharat, R. A. Mane, *Synth. Commun.* 2017, 47, 1777–1782.